Integra LifeSciences (IART) Q1 2026 Earnings
Reported May 5, 2026 at 6:15 AM ET · SEC Source
Q1 26 EPS
$0.54
BEAT +33.37%
Est. $0.40
Q1 26 Revenue
$391.9M
BEAT +2.66%
Est. $381.8M
vs S&P Since Q1 26
+36.3%
BEATING MARKET
IART +39.2% vs S&P +2.9%
Market Reaction
Did IART Beat Earnings? Q1 2026 Results
Integra LifeSciences delivered a strong first quarter for fiscal 2026, posting adjusted EPS of $0.54 against a consensus estimate of $0.40, a beat of 33.37%, while revenue of $391.92 million edged past the $381.77 million estimate by 2.66% and grew 2… Read more Integra LifeSciences delivered a strong first quarter for fiscal 2026, posting adjusted EPS of $0.54 against a consensus estimate of $0.40, a beat of 33.37%, while revenue of $391.92 million edged past the $381.77 million estimate by 2.66% and grew 2.4% year over year. The headline story behind the outperformance was a meaningful acceleration in the Tissue Reconstruction segment, which grew 6.7% on a reported basis and posted double-digit gains in Integra Skin, DuraSorb, and a relaunched PriMatrix, helping offset softer results in Specialty Surgery where organic revenue declined 0.6%. Operational improvement was equally evident in the margin profile, with adjusted EBITDA margin expanding to 19.4% from 16.6% a year ago and the GAAP net loss narrowing sharply to $4.62 million from $25.29 million, in part as costs tied to the Boston Recall and Braintree Transition continued to ease. Stuart Essig, who returned to the chief executive role, has emphasized commercial execution and organizational culture as priorities, and the company raised its full-year 2026 adjusted EPS guidance to $2.40-$2.50 while reaffirming revenue guidance of $1.66 billion to $1.70 billion.
Key Takeaways
- • Improved supply reliability driving strong growth in Integra Skin
- • Successful relaunch of PriMatrix and Durepair
- • Neurosurgery organic growth of 1.9% driven by Certas Plus, CUSA, and Bactiseal
- • Adjusted gross margin expansion to 64.1% from 62.2%
- • Reduced Boston Recall/Braintree Transition charges
- • Benefits from IEEPA tariffs supporting EPS guidance raise
IART Forward Guidance & Outlook
For Q2 2026, the company expects reported revenues of $410 million to $425 million (reported growth of -1.3% to 2.3%, organic growth of -1.5% to 2.1%) and adjusted EPS of $0.44 to $0.52. For full year 2026, the company reaffirmed revenue guidance of $1.662 billion to $1.702 billion (reported growth of 1.6% to 4.1%, organic growth of 0.8% to 3.3%) and raised adjusted EPS guidance to $2.40 to $2.50 (from prior $2.30 to $2.40), reflecting first quarter benefits from IEEPA tariffs. The company remains on track to begin SurgiMend production by end of June 2026 to support a fourth quarter launch.
IART YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
IART Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our first-quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold.”
— Mojdeh Poul, Q1 2026 Earnings Press Release
IART Earnings Trends
IART vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
IART EPS Trend
Earnings per share: estimate vs actual
IART Revenue Trend
Quarterly revenue: estimate vs actual
IART Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.40 | $0.54 | +33.37% | $391.9M | +2.66% |
| Q4 25 BEAT FY | $0.80 | $0.83 | +3.72% | $434.9M | +1.23% |
| FY Full Year | — | $2.23 | — | $1.64B | — |
| Q3 25 BEAT | $0.44 | $0.54 | +24.14% | $402.1M | -2.96% |
| Q2 25 BEAT | $0.43 | $0.45 | +4.38% | $415.6M | +5.20% |